Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Guillermo Garcia-Manero, Gail Roboz, Katherine Walsh, Hagop Kantarjian, Ellen Ritchie, Patricia Kropf, Casey O'Connell, Raoul Tibes, Scott Lunin, Todd Rosenblat, Karen Yee, Wendy Stock, Elizabeth Griffiths, Joseph Mace, Nikolai Podoltsev, Jesus Berdeja, Elias Jabbour, Jean Pierre J. Issa, Yong Hao, Harold N. KeerMohammad Azab, Michael R. Savona

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences